Abstract
The androgen-receptor pathway inhibitors (ARPI) are standard treatment of metastatic castration-resistant prostate cancer (mCRPC). However, the mechanisms of both primary and acquired resistance remain largely unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have